„MSD is a world leader in oncology. Visionary research and collaborative action have already led to breakthroughs for the prevention and treatment of certain types of cancer and we're committed to driving further innovation to help change the future of this disease.”
Will Wooding, Oncology Business Unit Director, Switzerland
Switzerland is one of more than fifty countries in which MSD conducts clinical research. The growing Swiss oncology clinical trial program is coordinated at our site in the Citybay building in Lucerne.
Also our site in Schachen in the canton of Lucerne plays an important role in providing new innovative medicines. Around 330 employees from currently 15 nations work here to
Improving access to cancer care is our strategic priority. We are working with the entire cancer community to help patients gain access to the oncology medicines that they need and to expand the provision of quality cancer care.
In our office at the Citybay building in Lucerne, the Swiss Oncology team is
MSD Switzerland has engaged in collaborative efforts to raise the awareness of cancer and improve its prevention, including
We participate in several initiatives to support patients with cancer. These include: